BAROSTIM NEO™

CVRx® has developed a proprietary implantable technology designed for the treatment of heart failure and high blood pressure.

BAROSTIM NEO™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. BAROSTIM NEO™ can be adjusted to meet each patient’s individual therapy needs.

A small device with a powerful effect

BAROSTIM THERAPY™ is effectively administered through BAROSTIM NEO™, a minimally-invasive, long-lasting device.

Subcutaneous, implantable system:

BAROSTIM NEO Carotid Sinus Lead Implantable Pulse Generator (IPG) Device:

Carotid Sinus Lead:
A 2mm electrode is attached to the carotid artery and connected to the IPG, with the design to electrically activate the baroreceptors.

Implantable Pulse Generator (IPG) Device:
An implantable pulse generator is inserted under the skin, below the collar bone, delivering an electrical stimulation through the lead.

Wireless Programmer System:
A programmer system enables the clinician to customize therapy to the patients’ needs. The unique on/off capability can promote the observation of the differences that BAROSTIM THERAPY™ makes in blood pressure and other hemodynamic parameters.

For more information, please visit www.BAROSTIMTHERAPY.com

EUROPE:  The BAROSTIM NEO™ System is CE Marked and approved for sale for hypertension patients in the European Union (EU). It is also CE Marked and approved for sale for heart failure patients in the EU.

UNITED STATES:
CAUTION:  Investigational device. Limited by Federal (or United States) law to investigational use.
CAUTION:  Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal law for use in the treatment of resistant hypertensive patients implanted with the Rheos CSL leads.  The effectiveness of this device has not been demonstrated.

CANADA ONLY:  CAUTION: Exclusively for Clinical Investigations

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/